AMGN Stock Recent News
AMGN LATEST HEADLINES
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.
In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns.
The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.